Expertise in
5
conditions

Dr. Roger J. Bedimo

Infectious Disease
Vantxhcs
4500 S Lancaster Rd, 
Dallas, TX 
31 Years of Experience
Expertise in
5
conditions
Vantxhcs
4500 S Lancaster Rd, 
Dallas, TX 

Overview

Roger Bedimo is an Infectious Disease provider practicing medicine in Dallas, Texas. He has been practicing medicine for over 31 years.

Dr. Bedimo is highly rated in 5 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Hepatitis C, Sepsis, and COVID-19.

He is actively involved in clinical research, co-authoring 126 peer reviewed articles and participating in 10 clinical trials.

Specialties

Infectious Disease

Licenses

Internal Medicine in AL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Vantxhcs
4500 S Lancaster Rd, Dallas, TX 75216

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Assessing the Impact of Providing Pharmacists With Medical Records in a Patient-Centered, Community Pharmacy-Based, HIV Care Model
Assessing the Impact of Providing Pharmacists With Medical Records in a Patient-Centered, Community Pharmacy-Based, HIV Care Model
Enrollment Status: Terminated
Publish Date: July 18, 2025
Intervention Type: Other
Study Phase: Not Applicable
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: Glecaprevir+Pibrentasvir, Ribavirin
Study Phase: Phase 2
Integrated Stepped Care for Unhealthy Alcohol Use in HIV
Integrated Stepped Care for Unhealthy Alcohol Use in HIV
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Other
Study Phase: Not Applicable
Impact of HCV Therapy on Cardiovascular Risk and Bone Health
Impact of HCV Therapy on Cardiovascular Risk and Bone Health
Enrollment Status: Terminated
Publish Date: August 19, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Enrollment Status: Completed
Publish Date: April 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

126 Total Publications

A Duty to Act.
A Duty to Act.
Journal: The American journal of tropical medicine and hygiene
Published: August 05, 2026
Similar Doctors
Expertise in
36
conditions
Dr. Cedric W. Spak
Infectious Disease
Expertise in
36
conditions
Dr. Cedric W. Spak
Infectious Disease
Referral may be required
Before you request

Cedric Spak, M.D., PA

3410 Worth Street,, Suite #780, 
Dallas, TX 
 (6.6 miles away)
214-716-0662
Languages Spoken:
English, German, Polish, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Cedric Spak is an Infectious Disease provider practicing medicine in Dallas, Texas. Dr. Spak is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Actinomycosis, Cytomegalic Inclusion Disease, Osteomyelitis, and Cytomegalovirus Infection. Dr. Spak is board certified in Infectious Disease- American Board Of Internal Medicine, Infectious Disease- American Board Of Internal Med/Infectious Disease, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. Dr. Spak is currently accepting new patients.

Expertise in
16
conditions
Dr. Mahesh B. Kottapalli
Infectious Disease
Expertise in
16
conditions
Dr. Mahesh B. Kottapalli
Infectious Disease
Referral may be required

Poornima Chadalawada MD PA

2727 Bolton Boone Dr Ste 109, 
Desoto, TX 
 (7.7 miles away)
972-283-2370
Languages Spoken:
English, Hindi, Kannada, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Mahesh Kottapalli is an Infectious Disease provider practicing medicine in Desoto, Texas. Dr. Kottapalli is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Osteomyelitis, Osteomyelitis in Children, Cellulitis, and Lymphangitis. Dr. Kottapalli is currently accepting new patients.

Expertise in
4
conditions
Dr. Amneris E. Luque
Infectious Disease
Expertise in
4
conditions
Dr. Amneris E. Luque
Infectious Disease
Referral may be required

Dallas County Hospital District

5200 Harry Hines Blvd, 
Dallas, TX 
 (8.6 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances

Amneris Luque is an Infectious Disease provider practicing medicine in Dallas, Texas. Dr. Luque is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

Frequently Asked Questions about Dr. Roger J. Bedimo

How do I make an appointment with Dr. Roger J. Bedimo?

You can book an appointment with Dr. Roger J. Bedimo by calling their office at 214-857-0397. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Roger J. Bedimo a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Roger J. Bedimo is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Roger J. Bedimo specialize in?

While Dr. Roger J. Bedimo is a Infectious Disease, they have specific expertise in HIV/AIDS, Hepatitis C, and Sepsis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Roger J. Bedimo participate in research or clinical trials?

Yes. Dr. Roger J. Bedimo has published 126 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Roger J. Bedimo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Roger J. Bedimo accept my insurance?

Dr. Roger J. Bedimo accepts most major insurance plans, including Health Care Services Corporation and Wellcare. We recommend calling the office directly at 214-857-0397 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bedimo's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile